Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
ObjectiveTo investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.Patients and methods1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 regist...
Saved in:
| Published in | Rheumatic & musculoskeletal diseases open Vol. 9; no. 1; p. e002936 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
EULAR
01.03.2023
BMJ Publishing Group LTD BMJ Publishing Group |
| Series | Original research |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2056-5933 2056-5933 |
| DOI | 10.1136/rmdopen-2022-002936 |
Cover
| Abstract | ObjectiveTo investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.Patients and methods1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model.ResultsThe distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i.ConclusionCOVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation. |
|---|---|
| AbstractList | Objective To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.Patients and methods 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model.Results The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i.Conclusion COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation. ObjectiveTo investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.Patients and methods1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model.ResultsThe distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i.ConclusionCOVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation. To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies. 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model. The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i. COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation. To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.OBJECTIVETo investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model.PATIENTS AND METHODS1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model.The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i.RESULTSThe distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i.COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation.CONCLUSIONCOVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation. |
| Author | Ros-Vilamajo, Inmaculada Caliz, Rafael Álvaro-Gracia, José M Castrejon, Isabel Mateo Soria, Lourdes Garcia-Dorta, Alicia Freire-González, Mercedes Sánchez-Alonso, Fernando Diaz-Gonzalez, Federico Rodríguez-Lozano, Carlos González-Dávila, Enrique Campos, Cristina Manrique-Arija, Sara Bohorquez, Cristina Sanchez-Piedra, Carlos Ruiz-Montesinos, Dolores Busquets, Noemí Rosello, Rosa Culqui, Dante |
| AuthorAffiliation | 8 Rheumatology Department , Hospital Universitario Virgen Macarena , Sevilla , Spain 19 Department of Internal Medicine, Dermatology and Psychiatry , Universidad de La Laguna , La Laguna , Spain 14 Rheumatology Department , Hospital Universitari Germans Trias i Pujol , Badalona , Spain 10 Rheumatology Department , Hospital Universitario Insulsar Gran Canaria Doctor Negrin , Las Palmas de Gran Canaria , Spain 13 Rheumatology , Hospital Universitario Príncipe de Asturias , Alcala de Henares , Spain 6 Rheumatology Department , Consorci Hospital General Universitari de Valencia , Valencia , Spain 7 Rheumatology Department , Hospital Regional Universitario de Málaga , Malaga , Spain 4 Rheumatology Department , Hospital General San Jorge , Huesca , Spain 11 Rheumatology , Complejo Hospitalario Universitario A Coruña Biblioteca , A Coruna , Spain 18 Departamento de Estadística e Investigación Operativa , Universidad de La Laguna , La Laguna , Spain 1 Rheumatology Department , Hospital General Universit |
| AuthorAffiliation_xml | – name: 15 Rheumatology Department , Hospital General de Granollers , Granollers , Spain – name: 7 Rheumatology Department , Hospital Regional Universitario de Málaga , Malaga , Spain – name: 8 Rheumatology Department , Hospital Universitario Virgen Macarena , Sevilla , Spain – name: 2 Spanish Agency of Health Technology Assessment , Instituto de Salud Carlos III , Madrid , Spain – name: 17 Research Unit , Instituto de Investigacion Sanitaria Gregorio Maranon , Madrid , Spain – name: 10 Rheumatology Department , Hospital Universitario Insulsar Gran Canaria Doctor Negrin , Las Palmas de Gran Canaria , Spain – name: 13 Rheumatology , Hospital Universitario Príncipe de Asturias , Alcala de Henares , Spain – name: 19 Department of Internal Medicine, Dermatology and Psychiatry , Universidad de La Laguna , La Laguna , Spain – name: 9 Rheumatology , Hospital Son Llatzer , Palma de Mallorca , Spain – name: 11 Rheumatology , Complejo Hospitalario Universitario A Coruña Biblioteca , A Coruna , Spain – name: 16 Rheumatology , Hospital General Universitario Gregorio Marañón , Madrid , Spain – name: 6 Rheumatology Department , Consorci Hospital General Universitari de Valencia , Valencia , Spain – name: 3 Research Unit , Spanish Society of Rheumatology , Madrid , Spain – name: 18 Departamento de Estadística e Investigación Operativa , Universidad de La Laguna , La Laguna , Spain – name: 5 Rheumatology Department , Hospital Universitario de Canarias , La Laguna , Spain – name: 14 Rheumatology Department , Hospital Universitari Germans Trias i Pujol , Badalona , Spain – name: 4 Rheumatology Department , Hospital General San Jorge , Huesca , Spain – name: 1 Rheumatology Department , Hospital General Universitario Gregorio Maranon , Madrid , Spain – name: 12 Rheumatology Department , Hospital Universitario Virgen de las Nieves , Granada , Spain |
| Author_xml | – sequence: 1 givenname: José M surname: Álvaro-Gracia fullname: Álvaro-Gracia, José M organization: Rheumatology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain – sequence: 2 givenname: Carlos surname: Sanchez-Piedra fullname: Sanchez-Piedra, Carlos organization: Spanish Agency of Health Technology Assessment, Instituto de Salud Carlos III, Madrid, Spain – sequence: 3 givenname: Dante surname: Culqui fullname: Culqui, Dante organization: Research Unit, Spanish Society of Rheumatology, Madrid, Spain – sequence: 4 givenname: Rosa surname: Rosello fullname: Rosello, Rosa organization: Rheumatology Department, Hospital General San Jorge, Huesca, Spain – sequence: 5 givenname: Alicia surname: Garcia-Dorta fullname: Garcia-Dorta, Alicia organization: Rheumatology Department, Hospital Universitario de Canarias, La Laguna, Spain – sequence: 6 givenname: Cristina surname: Campos fullname: Campos, Cristina organization: Rheumatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain – sequence: 7 givenname: Sara orcidid: 0000-0003-2284-7846 surname: Manrique-Arija fullname: Manrique-Arija, Sara organization: Rheumatology Department, Hospital Regional Universitario de Málaga, Malaga, Spain – sequence: 8 givenname: Dolores surname: Ruiz-Montesinos fullname: Ruiz-Montesinos, Dolores organization: Rheumatology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain – sequence: 9 givenname: Inmaculada surname: Ros-Vilamajo fullname: Ros-Vilamajo, Inmaculada organization: Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain – sequence: 10 givenname: Carlos surname: Rodríguez-Lozano fullname: Rodríguez-Lozano, Carlos organization: Rheumatology Department, Hospital Universitario Insulsar Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain – sequence: 11 givenname: Mercedes surname: Freire-González fullname: Freire-González, Mercedes organization: Rheumatology, Complejo Hospitalario Universitario A Coruña Biblioteca, A Coruna, Spain – sequence: 12 givenname: Rafael surname: Caliz fullname: Caliz, Rafael organization: Rheumatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain – sequence: 13 givenname: Cristina surname: Bohorquez fullname: Bohorquez, Cristina organization: Rheumatology, Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain – sequence: 14 givenname: Lourdes surname: Mateo Soria fullname: Mateo Soria, Lourdes organization: Rheumatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain – sequence: 15 givenname: Noemí surname: Busquets fullname: Busquets, Noemí organization: Rheumatology Department, Hospital General de Granollers, Granollers, Spain – sequence: 16 givenname: Isabel surname: Castrejon fullname: Castrejon, Isabel organization: Research Unit, Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain – sequence: 17 givenname: Fernando surname: Sánchez-Alonso fullname: Sánchez-Alonso, Fernando organization: Research Unit, Spanish Society of Rheumatology, Madrid, Spain – sequence: 18 givenname: Enrique surname: González-Dávila fullname: González-Dávila, Enrique organization: Departamento de Estadística e Investigación Operativa, Universidad de La Laguna, La Laguna, Spain – sequence: 19 givenname: Federico orcidid: 0000-0002-4139-9295 surname: Diaz-Gonzalez fullname: Diaz-Gonzalez, Federico email: federico.diaz.gonzalez@gmail.com organization: Department of Internal Medicine, Dermatology and Psychiatry, Universidad de La Laguna, La Laguna, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36927849$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstqGzEUHUpKk7r5gkIRdNPNNHrNQ6tSnLQ1BAJ9bYVGurJl7JEraVz8Lf3Zyh6ndbIICCTuPefo6Oq8LM5630NRvCb4PSGsvgpr4zfQlxRTWmJMBaufFRcUV3VZCcbOTs7nxWWMS4wx4Yw1hL0ozlktaNNycVH8ubEWdIrIWzS9-zm7LolAW6W161Vyvkd5GRdBRUBKJ7d1aYdcjza5C33m_XZpgcIChrVK3hmkQloEl1xEqjdoE31wGapP6lkxqTCHBAalBQS1OSjm4-jg281XFNNgdq-K51atIlwe90nx49PN9-mX8vbu82z68bbsKo5TaSw3VSMwNhigE5bvn1lVumVAObOcUtJSy0VtOivamtO6sgACE8JbYyxjk2I26hqvlnIT3FqFnfTKyUPBh7nM7p1egeTacquo4oJUXIAWgjDOGwGdxlRXbdb6MGpthm4NRucZBbV6IPqw07uFnPutJBgzTNu9m3dHheB_DRCTXLuoYbVSPfghyvxxbYtJk2-eFG8fQZd-CH2e1QFFmqau96g3p5b-ebkPQQaIEaCDjzGAldqlw-9nh26Vrcl95uQxc3KfOTlmLnPZI-69_NOsq5HVrZf_PT_F-Avzb-yB |
| CitedBy_id | crossref_primary_10_3389_fimmu_2024_1503895 crossref_primary_10_1136_rmdopen_2023_003022 crossref_primary_10_1016_j_cmi_2025_02_030 crossref_primary_10_1016_j_rdc_2024_08_005 crossref_primary_10_1016_j_rhum_2023_09_023 crossref_primary_10_1007_s00296_024_05742_x crossref_primary_10_1080_14740338_2023_2267971 crossref_primary_10_4078_jrd_2023_0054 crossref_primary_10_3346_jkms_2023_38_e247 crossref_primary_10_1186_s41927_024_00396_5 |
| Cites_doi | 10.3402/jmahp.v3.27041 10.1111/jocd.14613 10.1136/ard.2004.032482 10.1016/S2665-9913(21)00222-8 10.1111/jdv.17502 10.3390/jpm11121283 10.1002/acr2.11336 10.1136/annrheumdis-2021-220461 10.1001/jama.2021.7489 10.1136/annrheumdis-2021-220732 10.1161/CIRCULATIONAHA.121.056135 10.1136/rmdopen-2019-001035 10.1093/rheumatology/kel414 10.1136/rmdopen-2021-001925 10.1002/art.21235 10.3390/vaccines9050435 10.1136/bcr-2021-246533 10.1016/S2665-9913(20)30396-9 10.1001/jamacardio.2021.2833 10.3389/fcvm.2021.759119 10.1007/s00415-021-10780-7 10.1186/ar3021 10.1002/art.41924 10.1016/S2665-9913(21)00108-9 10.1016/j.reumae.2017.08.005 10.3390/vaccines9101108 10.1136/annrheumdis-2021-221490 10.1016/j.ijid.2022.01.031 10.1093/rheumatology/keac249 10.3389/fpubh.2021.778964 10.1136/annrheumdis-2021-221145 10.1136/annrheumdis-2021-221571 10.1002/art.1780380107 10.1136/annrheumdis-2021-220503 10.1001/JAMA.2021.7489 10.1136/annrheumdis-2021-eular.1359 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. 2023 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. – notice: 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. 2023 |
| DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR BTHHO CCPQU COVID DWQXO FYUFA GHDGH K9. PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1136/rmdopen-2022-002936 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central BMJ Journals ProQuest One Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2056-5933 |
| ExternalDocumentID | oai_doaj_org_article_4cf4fa2a491549ec99134479ebc02c58 PMC10030283 36927849 10_1136_rmdopen_2022_002936 rmdopen |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Netherlands |
| GeographicLocations_xml | – name: Netherlands |
| GrantInformation_xml | – fundername: Bristol-Myers Squibb funderid: http://dx.doi.org/10.13039/100002491 – fundername: Roche funderid: http://dx.doi.org/10.13039/100004337 – fundername: Galápagos funderid: http://dx.doi.org/10.13039/100019832 – fundername: ; |
| GroupedDBID | 53G 5VS 7X7 8FI 8FJ 9YT ABUWG ACMMV ADBBV AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV BENPR BTFSW BTHHO CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE HZ~ KQ8 M48 M~E O9- OK1 PGMZT PHGZT PIMPY PQQKQ PROAC RHI RMJ RPM UKHRP AAYXX ADRAZ CITATION PHGZM PJZUB PPXIY PUEGO 3V. CGR CUY CVF ECM EIF NPM RHF 7XB 8FK AZQEC COVID DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-b540t-df4d57900d0eeb9f4433755c83e243f422182f496dbf9864265fee901148ddf33 |
| IEDL.DBID | M48 |
| ISSN | 2056-5933 |
| IngestDate | Wed Aug 27 01:19:31 EDT 2025 Thu Aug 21 18:37:55 EDT 2025 Fri Sep 05 14:48:05 EDT 2025 Fri Jul 25 10:22:48 EDT 2025 Thu Jan 02 22:53:43 EST 2025 Thu Sep 11 00:34:42 EDT 2025 Thu Apr 24 22:57:55 EDT 2025 Thu Apr 24 22:49:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 Rheumatoid Arthritis Psoriatic Arthritis Vaccination |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b540t-df4d57900d0eeb9f4433755c83e243f422182f496dbf9864265fee901148ddf33 |
| Notes | Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-4139-9295 0000-0003-2284-7846 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1136/rmdopen-2022-002936 |
| PMID | 36927849 |
| PQID | 2788177661 |
| PQPubID | 2041888 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4cf4fa2a491549ec99134479ebc02c58 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10030283 proquest_miscellaneous_2788801791 proquest_journals_2788177661 pubmed_primary_36927849 crossref_citationtrail_10_1136_rmdopen_2022_002936 crossref_primary_10_1136_rmdopen_2022_002936 bmj_journals_10_1136_rmdopen_2022_002936 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-03-01 |
| PublicationDateYYYYMMDD | 2023-03-01 |
| PublicationDate_xml | – month: 03 year: 2023 text: 2023-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationSeriesTitle | Original research |
| PublicationTitle | Rheumatic & musculoskeletal diseases open |
| PublicationTitleAbbrev | RMD Open |
| PublicationTitleAlternate | RMD Open |
| PublicationYear | 2023 |
| Publisher | EULAR BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: EULAR – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Khayat-Khoei, Bhattacharyya, Katz (R24) 2022; 269 Aletaha, Ward, Machold (R18) 2005; 52 Watad, De Marco, Mahajna (R22) 2021; 9 Chiang, Connolly, Ruddy (R6) 2021; 80 Quattrini, Verardi, Caldarola (R21) 2021; 35 Iikuni, Nakajima, Inoue (R23) 2007; 46 Terracina, Tan (R19) 2021; 3 Amiya, Fujimoto, Matsumoto (R30) 2022; 116 Rondaan, Furer, Heijstek (R2) 2019; 5 Braun-Moscovici, Kaplan, Braun (R5) 2021; 80 Bixio, Bertelle, Masia (R11) 2021; 3 Boyarsky, Werbel, Avery (R4) 2021; 325 Li, Tong, Yeung (R12) 2022; 81 Boekel, Steenhuis, Hooijberg (R3) 2021; 3 Lindqvist, Wernroth, Husmark (R34) 2017; 35 Álvaro Gracia, Sanchez-Piedra, Manero (R15) 2021; 7 Yamamoto, Mashiba, Takano (R29) 2021; 9 Lui, Lee, Lee (R28) 2021; 9 Perrot, Hemon, Busnel (R20) 2021; 3 Montgomery, Ryan, Engler (R27) 2021; 6 Connolly, Ruddy, Boyarsky (R9) 2022; 74 Rémy, Zöllner, Heckmann (R1) 2015; 3 Alania-Torres, Morillas-Climent, García-Escrivá (R25) 2021; 8 Simon, Tascilar, Fagni (R7) 2021; 80 Barbhaiya, Levine, Bykerk (R8) 2021; 80 Machado, Lawson-Tovey, Strangfeld (R10) 2022; 81 Sanchez-Piedra, Hernández Miguel, Manero (R16) 2019; 15 Pinte, Negoi, Ionescu (R13) 2021; 11 Saber, Ng, Renard (R33) 2010; 12 Shimagami, Yamaguchi, Kato (R32) 2022; 15 Gladman, Antoni, Mease (R35) 2005; 64 Suppl 2 Rider, Parks, Wilkerson (R14) 2022; 61 Prevoo, van’t Hof, Kuper (R17) 1995; 38 Temiz, Abdelmaksoud, Wollina (R31) 2022; 21 Bozkurt, Kamat, Hotez (R26) 2021; 144 Temiz (2025090312301527000_9.1.e002936.31) 2022; 21 2025090312301527000_9.1.e002936.23 2025090312301527000_9.1.e002936.26 Alania-Torres (2025090312301527000_9.1.e002936.25) 2021; 8 Montgomery (2025090312301527000_9.1.e002936.27) 2021; 6 Pinte (2025090312301527000_9.1.e002936.13) 2021; 11 Saber (2025090312301527000_9.1.e002936.33) 2010; 12 Boekel (2025090312301527000_9.1.e002936.3) 2021; 3 Khayat-Khoei (2025090312301527000_9.1.e002936.24) 2022; 269 2025090312301527000_9.1.e002936.4 2025090312301527000_9.1.e002936.5 2025090312301527000_9.1.e002936.6 2025090312301527000_9.1.e002936.7 Sanchez-Piedra (2025090312301527000_9.1.e002936.16) 2019; 15 2025090312301527000_9.1.e002936.8 Shimagami (2025090312301527000_9.1.e002936.32) 2022; 15 Rider (2025090312301527000_9.1.e002936.14) 2022; 61 2025090312301527000_9.1.e002936.10 Lindqvist (2025090312301527000_9.1.e002936.34) 2017; 35 2025090312301527000_9.1.e002936.1 2025090312301527000_9.1.e002936.12 Terracina (2025090312301527000_9.1.e002936.19) 2021; 3 2025090312301527000_9.1.e002936.17 2025090312301527000_9.1.e002936.18 Amiya (2025090312301527000_9.1.e002936.30) 2022; 116 Álvaro Gracia (2025090312301527000_9.1.e002936.15) 2021; 7 Perrot (2025090312301527000_9.1.e002936.20) 2021; 3 Connolly (2025090312301527000_9.1.e002936.9) 2022; 74 Watad (2025090312301527000_9.1.e002936.22) 2021; 9 Yamamoto (2025090312301527000_9.1.e002936.29) 2021; 9 Lui (2025090312301527000_9.1.e002936.28) 2021; 9 Gladman (2025090312301527000_9.1.e002936.35) 2005; 64 Suppl 2 Rondaan (2025090312301527000_9.1.e002936.2) 2019; 5 Bixio (2025090312301527000_9.1.e002936.11) 2021; 3 Quattrini (2025090312301527000_9.1.e002936.21) 2021; 35 |
| References_xml | – volume: 3 year: 2015 ident: R1 article-title: Vaccination: the cornerstone of an efficient healthcare system publication-title: J Mark Access Health Policy doi: 10.3402/jmahp.v3.27041 – volume: 21 start-page: 4 year: 2022 ident: R31 article-title: Cutaneous and allergic reactions due to COVID-19 vaccinations: a review publication-title: J Cosmet Dermatol doi: 10.1111/jocd.14613 – volume: 64 Suppl 2 start-page: ii14 year: 2005 ident: R35 article-title: Psoriatic arthritis: epidemiology, clinical features, course, and outcome publication-title: Ann Rheum Dis doi: 10.1136/ard.2004.032482 – volume: 3 start-page: e778 year: 2021 ident: R3 article-title: Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00222-8 – volume: 35 start-page: e727 year: 2021 ident: R21 article-title: New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after sars-cov-2 vaccination publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.17502 – volume: 11 start-page: 1283 year: 2021 ident: R13 article-title: COVID-19 vaccine does not increase the risk of disease flare-ups among patients with autoimmune and immune-mediated diseases publication-title: J Pers Med doi: 10.3390/jpm11121283 – volume: 35 start-page: 936 year: 2017 ident: R34 article-title: DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis publication-title: The Swedish Early Psoriatic Arthritis Cohort Clin Exp Rheumatol – volume: 3 start-page: 832 year: 2021 ident: R11 article-title: Incidence of disease flare after BNT162b2 coronavirus disease 2019 vaccination in patients with rheumatoid arthritis in remission publication-title: ACR Open Rheumatol doi: 10.1002/acr2.11336 – volume: 80 start-page: 1312 year: 2021 ident: R7 article-title: SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-220461 – volume: 325 start-page: 2204 year: 2021 ident: R4 article-title: Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients publication-title: JAMA doi: 10.1001/jama.2021.7489 – volume: 80 start-page: 1352 year: 2021 ident: R8 article-title: Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-220732 – volume: 144 start-page: 471 year: 2021 ident: R26 article-title: Myocarditis with COVID-19 mRNA vaccines publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.121.056135 – volume: 5 year: 2019 ident: R2 article-title: Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations publication-title: RMD Open doi: 10.1136/rmdopen-2019-001035 – volume: 46 start-page: 846 year: 2007 ident: R23 article-title: What’s in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kel414 – volume: 7 year: 2021 ident: R15 article-title: Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study publication-title: RMD Open doi: 10.1136/rmdopen-2021-001925 – volume: 52 start-page: 2625 year: 2005 ident: R18 article-title: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states publication-title: Arthritis Rheum doi: 10.1002/art.21235 – volume: 9 year: 2021 ident: R22 article-title: Immune-mediated disease flares or new-onset disease in 27 subjects following mrna/DNA SARS-CoV-2 vaccination publication-title: Vaccines (Basel) doi: 10.3390/vaccines9050435 – volume: 15 year: 2022 ident: R32 article-title: Marked increase of interferon-β after bnt162b2 mrna vaccination: a case of polyarthritis with pleurisy publication-title: BMJ Case Rep doi: 10.1136/bcr-2021-246533 – volume: 3 start-page: e6 year: 2021 ident: R20 article-title: First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(20)30396-9 – volume: 6 start-page: 1202 year: 2021 ident: R27 article-title: Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2021.2833 – volume: 8 start-page: 759119 year: 2021 ident: R25 article-title: Case report: probable myocarditis after covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy publication-title: Front Cardiovasc Med doi: 10.3389/fcvm.2021.759119 – volume: 269 start-page: 1093 year: 2022 ident: R24 article-title: COVID-19 mRNA vaccination leading to CNS inflammation: a case series publication-title: J Neurol doi: 10.1007/s00415-021-10780-7 – volume: 12 year: 2010 ident: R33 article-title: Remission in psoriatic arthritis: is it possible and how can it be predicted? publication-title: Arthritis Res Ther doi: 10.1186/ar3021 – volume: 74 start-page: 28 year: 2022 ident: R9 article-title: Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination publication-title: Arthritis Rheumatol doi: 10.1002/art.41924 – volume: 3 start-page: e469 year: 2021 ident: R19 article-title: Flare of rheumatoid arthritis after COVID-19 vaccination publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00108-9 – volume: 15 start-page: 229 year: 2019 ident: R16 article-title: Objectives and methodology of BIOBADASER phase III publication-title: Reumatología Clínica (English Edition) doi: 10.1016/j.reumae.2017.08.005 – volume: 9 year: 2021 ident: R29 article-title: A case of exacerbation of subclinical hyperthyroidism after first administration of BNT162b2 mRNA COVID-19 vaccine publication-title: Vaccines (Basel) doi: 10.3390/vaccines9101108 – volume: 81 start-page: 695 year: 2022 ident: R10 article-title: Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR coronavirus vaccine (COVAX) physician-reported registry publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-221490 – volume: 116 start-page: 255 year: 2022 ident: R30 article-title: Case report: acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2022.01.031 – volume: 61 start-page: SI143 year: 2022 ident: R14 article-title: Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keac249 – volume: 9 start-page: 778964 year: 2021 ident: R28 article-title: Development of graves’ disease after SARS-CoV-2 mRNA vaccination: a case report and literature review publication-title: Front Public Health doi: 10.3389/fpubh.2021.778964 – volume: 80 start-page: 1365 year: 2021 ident: R6 article-title: Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-221145 – volume: 81 start-page: 564 year: 2022 ident: R12 article-title: Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-221571 – volume: 38 start-page: 44 year: 1995 ident: R17 article-title: Modified disease activity scores that include twenty-eight-joint counts. development and validation in a prospective longitudinal study of patients with rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.1780380107 – volume: 80 start-page: 1317 year: 2021 ident: R5 article-title: Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the pfizer mRNA vaccine against SARS-CoV-2 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-220503 – volume: 7 year: 2021 ident: 2025090312301527000_9.1.e002936.15 article-title: Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study publication-title: RMD Open doi: 10.1136/rmdopen-2021-001925 – volume: 9 year: 2021 ident: 2025090312301527000_9.1.e002936.29 article-title: A case of exacerbation of subclinical hyperthyroidism after first administration of BNT162b2 mRNA COVID-19 vaccine publication-title: Vaccines (Basel) doi: 10.3390/vaccines9101108 – volume: 3 start-page: e778 year: 2021 ident: 2025090312301527000_9.1.e002936.3 article-title: Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00222-8 – volume: 35 start-page: 936 year: 2017 ident: 2025090312301527000_9.1.e002936.34 article-title: DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis publication-title: The Swedish Early Psoriatic Arthritis Cohort Clin Exp Rheumatol – ident: 2025090312301527000_9.1.e002936.17 doi: 10.1002/art.1780380107 – ident: 2025090312301527000_9.1.e002936.4 doi: 10.1001/JAMA.2021.7489 – volume: 74 start-page: 28 year: 2022 ident: 2025090312301527000_9.1.e002936.9 article-title: Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination publication-title: Arthritis Rheumatol doi: 10.1002/art.41924 – ident: 2025090312301527000_9.1.e002936.18 doi: 10.1002/art.21235 – ident: 2025090312301527000_9.1.e002936.5 doi: 10.1136/annrheumdis-2021-220503 – ident: 2025090312301527000_9.1.e002936.6 doi: 10.1136/annrheumdis-2021-eular.1359 – ident: 2025090312301527000_9.1.e002936.8 doi: 10.1136/annrheumdis-2021-220732 – volume: 12 year: 2010 ident: 2025090312301527000_9.1.e002936.33 article-title: Remission in psoriatic arthritis: is it possible and how can it be predicted? publication-title: Arthritis Res Ther doi: 10.1186/ar3021 – volume: 61 start-page: SI143 year: 2022 ident: 2025090312301527000_9.1.e002936.14 article-title: Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keac249 – volume: 11 start-page: 1283 year: 2021 ident: 2025090312301527000_9.1.e002936.13 article-title: COVID-19 vaccine does not increase the risk of disease flare-ups among patients with autoimmune and immune-mediated diseases publication-title: J Pers Med doi: 10.3390/jpm11121283 – volume: 21 start-page: 4 year: 2022 ident: 2025090312301527000_9.1.e002936.31 article-title: Cutaneous and allergic reactions due to COVID-19 vaccinations: a review publication-title: J Cosmet Dermatol doi: 10.1111/jocd.14613 – volume: 9 start-page: 778964 year: 2021 ident: 2025090312301527000_9.1.e002936.28 article-title: Development of graves’ disease after SARS-CoV-2 mRNA vaccination: a case report and literature review publication-title: Front Public Health doi: 10.3389/fpubh.2021.778964 – ident: 2025090312301527000_9.1.e002936.1 doi: 10.3402/jmahp.v3.27041 – volume: 116 start-page: 255 year: 2022 ident: 2025090312301527000_9.1.e002936.30 article-title: Case report: acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2022.01.031 – ident: 2025090312301527000_9.1.e002936.23 doi: 10.1093/rheumatology/kel414 – volume: 15 start-page: 229 year: 2019 ident: 2025090312301527000_9.1.e002936.16 article-title: Objectives and methodology of BIOBADASER phase III publication-title: Reumatología Clínica (English Edition) doi: 10.1016/j.reumae.2017.08.005 – volume: 269 start-page: 1093 year: 2022 ident: 2025090312301527000_9.1.e002936.24 article-title: COVID-19 mRNA vaccination leading to CNS inflammation: a case series publication-title: J Neurol doi: 10.1007/s00415-021-10780-7 – ident: 2025090312301527000_9.1.e002936.26 doi: 10.1161/CIRCULATIONAHA.121.056135 – ident: 2025090312301527000_9.1.e002936.7 doi: 10.1136/annrheumdis-2021-220461 – ident: 2025090312301527000_9.1.e002936.10 doi: 10.1136/annrheumdis-2021-221490 – volume: 3 start-page: 832 year: 2021 ident: 2025090312301527000_9.1.e002936.11 article-title: Incidence of disease flare after BNT162b2 coronavirus disease 2019 vaccination in patients with rheumatoid arthritis in remission publication-title: ACR Open Rheumatol doi: 10.1002/acr2.11336 – volume: 35 start-page: e727 year: 2021 ident: 2025090312301527000_9.1.e002936.21 article-title: New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after sars-cov-2 vaccination publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.17502 – volume: 8 start-page: 759119 year: 2021 ident: 2025090312301527000_9.1.e002936.25 article-title: Case report: probable myocarditis after covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy publication-title: Front Cardiovasc Med doi: 10.3389/fcvm.2021.759119 – ident: 2025090312301527000_9.1.e002936.12 doi: 10.1136/annrheumdis-2021-221571 – volume: 15 year: 2022 ident: 2025090312301527000_9.1.e002936.32 article-title: Marked increase of interferon-β after bnt162b2 mrna vaccination: a case of polyarthritis with pleurisy publication-title: BMJ Case Rep doi: 10.1136/bcr-2021-246533 – volume: 64 Suppl 2 start-page: ii14 year: 2005 ident: 2025090312301527000_9.1.e002936.35 article-title: Psoriatic arthritis: epidemiology, clinical features, course, and outcome publication-title: Ann Rheum Dis doi: 10.1136/ard.2004.032482 – volume: 3 start-page: e469 year: 2021 ident: 2025090312301527000_9.1.e002936.19 article-title: Flare of rheumatoid arthritis after COVID-19 vaccination publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(21)00108-9 – volume: 9 year: 2021 ident: 2025090312301527000_9.1.e002936.22 article-title: Immune-mediated disease flares or new-onset disease in 27 subjects following mrna/DNA SARS-CoV-2 vaccination publication-title: Vaccines (Basel) doi: 10.3390/vaccines9050435 – volume: 3 start-page: e6 year: 2021 ident: 2025090312301527000_9.1.e002936.20 article-title: First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection publication-title: Lancet Rheumatol doi: 10.1016/S2665-9913(20)30396-9 – volume: 6 start-page: 1202 year: 2021 ident: 2025090312301527000_9.1.e002936.27 article-title: Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2021.2833 – volume: 5 year: 2019 ident: 2025090312301527000_9.1.e002936.2 article-title: Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations publication-title: RMD Open doi: 10.1136/rmdopen-2019-001035 |
| SSID | ssj0001433713 |
| Score | 2.2873702 |
| Snippet | ObjectiveTo investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under... To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted... Objective To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under... |
| SourceID | doaj pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e002936 |
| SubjectTerms | Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - pathology Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - pathology Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines Cytokines Drug dosages Humans Immune system Interleukin-12 Interleukin-6 Patients Psoriatic Arthritis Rheumatic diseases Rheumatoid Arthritis Severe acute respiratory syndrome coronavirus 2 Vaccination Variables Vectors (Biology) |
| SummonAdditionalLinks | – databaseName: BMJ Open Access Journals dbid: 9YT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VIiEuiDeBgozEgQPpZmM7iY9QWhWkggQtKqcofnUX0aTaB3-GP8uM7d12EaqQctjEzsjrGcefPeNvAF6RzmVheK6bqsuFK0TeSetyyTtdaktRPLShf_SpOjwRH0_l6RYUq7Mws3NLaaN29fmPeKKBOJr6xUiNxiNHLiRe7dLG9A24SUxcFMSnvh9f7qoIznHZleiFxrxaCURrwFVXFIDTCIrfmIgCX_-_QObfsZJXJp-Du3AnoUb2Nqr5Hmy5_j7cOkp-8QfwO5IQz9ng2d7nbx_e52PFfnUGS0PPM7ySK4bRSQZKGMGmPUusqnNG27FsNnFLBLDD1DI0qEmgO2Jdb9nFfJiRCs2V5ygxRpE7y-IhriARf8YWfN3_wgJ37UM4Odg_3jvMU9qFXCN8W-TWCytrVRS2cE4rL6hPpTQNd6XgXpRE-u6Fqqz2RO5eVtI7p8LKylrP-SPY7ofePQHmuXLKa-6VkIJy2VlruEGQgrjSidpn8Bo10aZhM2_DioRXbVJaS0pro9IyKFfqak2iL6csGj-vf-nN-qWLyN5xffV3ZAfrqkS9HR4Ms7M2jeRWGC98V3ZCEbudM4piF0StnDZFaWSTwc7Kii7_WEms_XWNYCiDl-tiHMnknul6NyxjnYY-kFjncTS6dUt4pchDrDJoNsxxo6mbJf10EtjCx_QdRxD59P_7-hncxjseQ-12YHsxW7rniL0W-kUYbn8A564s3A priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZpDqGX0vTpJi0q9NBDTLyWZK-OaR6khbTQPMjNWNKI3dLYYR_5M_mzmZGUzW4p6aXgg7EkI2lG9jea0TeMfSKZq8KK3AyrNpdQyLxVDnIlWlMaR1E8tKF_8r06PpffLtXlUqovigmL9MBx4nal9dK3ZSs1kYmB1eQqlrUGY4vSqnDMt9DFkjEVdlekEGh-JZqhgah2J1eO8lGhVqD1Rb4oImV-Yq5-rfyQAm__38DmnzGTSz-ho-fsWUKPfC_2epOtQfeCbZwk__hLdhvJiKe893z_x8XXg3yg-U1rsTRIgOOVXDKcTjRQ4gg-7nhiV51y2pblkxHMEcj2Y8dxfkaB9oi3nePX035CorRLz_GNMZocHI-HucIb8Tb24PTwJw8ctq_Y-dHh2f5xntIv5AZh3Cx3XjpV66JwBYDRXtKcKmWHAkopvCyJ_N1LXTnjieS9rJQH0MHCcs4L8Zqtd30Hbxn3QoP2RngtlaScds5ZYRGsIL4EWfuMfUZJNGn5TJtgmYiqSUJrSGhNFFrGyntxNTbRmFM2jd-PN9pZNLqOLB6PV_9CerCoShTc4QEqZpMUs_mXYmZs-16LHgZWEnt_XSMoytjHRTGuaHLTtB3081hnSB9KrPMmKt2iJ6LS5CnWGRuuqONKV1dLuvEosIYP6HuOYPLd_xjcFnuK8yViMN42W59N5vAe0dnMfAgL8Q5UEjeu priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYkBAvE98EBjISDzxgLY3tJH5CMDYNpIEEDPUtir9oEUu6puWf4Z_lznbbFaFKeYhiJ3J8Z_vnu_PvCHmJMpe54UzXZcuEywVrpXVM8lYX2mIUDxr0zz-VZxfi41iOk8FtSGGVqzkxTNS2N2gjPyqQ97yqYDl5M7timDUKvasphcYeuTkCJIKpG6pxtbGxCM5hE5bIhka8PJpfWsxKBboBezD0SCE1856-_Lm1LAX2_v9Bzn8jJ68tRad3yEHCkPRtFPpdcsN198it8-Qlv0_-RErigfaeHn_-_uE9Gyn6uzVQGuRA4UqOGYrnGjB9BJ12NHGsDhSNs3Q-cUuAs_3UUlCvSSA_om1n6WyAfkGi12vP4YsxptxZGo90hS_CbWzB15MvNDDZPiAXpyffjs9YSsLANIC5BbNeWFmpPLe5c1p5gX0qpam5KwT3okAKeC9UabVHqveilN45FfZZ1nrOH5L9ru_cY0I9V055zb0SUmBmO2sNNwBZAGU6UfmMvAJJNGkQDU3Yn_CySUJrUGhNFFpGipW4GpPIzDGnxq_dL71evzSLXB67q79DPVhXRSLu8KCf_2jSuG6E8cK3RSsUct05ozCSQVTKaZMXRtYZOVxp0ebHNrqckRfrYhjX6KxpO9cvY50ap0uo8ygq3bolvFToL1YZqbfUcaup2yXddBK4w0c4qwOkfLK7XU_JbegJHoPtDsn-Yr50zwB9LfTzMMT-AiNsL3A priority: 102 providerName: ProQuest |
| Title | Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study |
| URI | https://rmdopen.bmj.com/content/9/1/e002936.full https://www.ncbi.nlm.nih.gov/pubmed/36927849 https://www.proquest.com/docview/2788177661 https://www.proquest.com/docview/2788801791 https://pubmed.ncbi.nlm.nih.gov/PMC10030283 https://doaj.org/article/4cf4fa2a491549ec99134479ebc02c58 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB41rVT1gng3pUSLxIEDBte7trMHhNqQqiCloNJU4WTZ-yCpWrs4CYLfwp9lZr0JDWorRY7lfWi9M2t_szP-BuAlyTwOFQ-KbpIHwoQiyGNtgpjnRVRoiuKhDf3BcXI0FJ9G8WgNFllR_QRObzTtKJ_UsL548-vH7_e44N_5jCRv60tNRShwNKzIzcSTFmw4hxHF8nm87zZdBOdolXn2oVvabsEmTyQ55BB2torL85VXlmP2vwmO_h9Vee01dXgf7nl8yfYbhXgAa6Z8CJsD70F_BH8auuIpqyzrfT77-CHYk-xnrrDUyYjhzzttGH3zQKkl2KRknn91ymjjltVjM0eoW000Q9UbO2IklpeaXU2rmoStrl3HHpt4c6NZ87mX6xFPmxF87Z8wx3L7GIaH_dPeUeATNAQFAr1ZoK3QcSrDUIfGFNIKmt44Vl1uIsGtiIge3gqZ6MISDXyUxNYY6WwwrS3nT2C9rEqzDcxyaaQtuJUiFpT1TmvFFcIZRKBGpLYNr1AS2UI_Mme78CTz8stIflkjvzZEC3FlyhOdU76Ni7sbvV42ump4Pu6ufkB6sKxKJN3uQlV_z_yaz4SywuZRLiTx4BklKcpBpNIUKoxU3G3D7kKL_t1YRPz-aYqwqQ0vlsW45smRk5emmjd1uvQoxTpPG6VbjmShum3orqjjylBXS8rJ2PGK79ETH-Hmzq2dPoMtnATexODtwvqsnpvnCMpmRQda6SjFo_x22oGN_d5gcIb_B_3jLycdt9HRcUvxL-m4Ogs |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviG8CA4wEEg9ES2Pnww8TYlunlq0FjW3aW4hjmxaxpPQDxN_C_8Lfxl3stCtCfZuUhyh2LCd3vjvfnX9HyEukeRQUzJdpnPtcB9zPI6X9iOUylAqzeNCh3x_E3VP-_jw63yB_mrMwmFbZyMRaUKuqQB_5doi450kC6uTt-LuPVaMwutqU0MhdaQW1U0OMuYMdh_rXT9jCTXd6-0DvV2F40DnZ6_quyoAvwVqZ-cpwFSUiCFSgtRSGc8aSKCpSpkPODA8R49xwEStpEMs8jCOjtag3EkoZdIiCCtjk6EBpkc3dzuDj8dLLg4O1mYM7arN4e3KhsC4WcCfsAjEmhuDQ1-TF1xXFWNcP-J_R-2_u5iVleHCb3HJWLH1n2e4O2dDlXXK97-L098hvC4o8pZWhex_Oevt-W9Af8PtG1vlI4XKhIYonK7CABR2V1KG8Tim6h-lkqOdgUFcjRYHBhzX8Es1LRcdToAxCzV56DiParHatqD1UVo8It3YGnzrHtMbSvU9Or4RAD0irrEr9iFDDhBZGMiN4xLG2nlIFK8BoAjtX88R45DVQInPLeJrVOyQWZ45oGRIts0TzSNiQKyscnDpW9fi2_qU3i5fGFk1kffdd5INFV4QCrx9Uky-ZkywZLww3eZhzgWh7uhCYS8EToWURhEWUemSr4aLlhy1Xk0deLJpBsmC4KC91Nbd9UhTY0OehZbrFTFgsMGItPJKusOPKVFdbytGwRi9vo14Bo_bx-nk9Jze6J_2j7Kg3OHxCbsJfYTb1b4u0ZpO5fgq24Ew-cwuOks9Xvcb_AokUcb4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkCZeEN8EBhgJJB6ImsZOUj8gBOuqlbGBgKG-ZYk_aBFLStOC-Fv4T_jruLOddkWob5PyEMWO5eQ-fL47_46QJ0jzJJIsLHtpEXId8bBIlA4TVpRxqTCLBx36R8fpwQl_M0pGW-RPexYG0ypbnWgVtaol-sg7MeKeZxksJx3j0yLe9wcvp99DrCCFkda2nIZjkUP96yds35oXwz7Q-mkcD_Y_7R2EvsJAWIKlMg-V4SrJRBSpSOtSGM4Zy5JE9piOOTM8Rnxzw0WqSoM45nGaGK2F3UQoZdAZCur_csY4x7IR2Shb-XdwqC7zQEddlnZmZworYgFfwv4Po2EIC32pPPu6tiTaygH_M3f_zdo8twwOrpGr3n6lrxzDXSdburpBdo58hP4m-e3gkBtaG7r37vOwH3YF_VFIaLU8QOHyQSGKZyqwdAWdVNTjuzYUHcN0NtYLMKXriaLA2mMLvESLStFpA3RAkNlzz2FEl8-uFXXHyeyIcOtm8HH_A7UourfIyYWQ5zbZrupK3yXUMKGFKZkRPOFYVU8pySSYS2Dhap6ZgDwDSuRegJvc7o1Ymnui5Ui03BEtIHFLrlx6IHWs5_Ft80vPly9NHY7I5u6vkQ-WXREE3D6oZ19yr1NyLg03RVxwgTh7WgrMouCZ0KWMYpn0ArLbctHqw1ZyFJDHy2bQKRgoKipdL1yfHqpq6HPHMd1yJiwVGKsWAemtsePaVNdbqsnY4pZ3cUUBc_be5nk9Ijsg2fnb4fHhfXIFfgpzOX-7ZHs-W-gHYATOy4dW2ig5vWjx_gtzqm9a |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+COVID-19+vaccination+on+disease+activity+in+patients+with+rheumatoid+arthritis+and+psoriatic+arthritis+on+targeted+therapy+in+the+COVIDSER+study&rft.jtitle=Rheumatic+%26+musculoskeletal+diseases+open&rft.au=%C3%81lvaro-Gracia%2C+Jos%C3%A9+M&rft.au=Sanchez-Piedra%2C+Carlos&rft.au=Culqui%2C+Dante&rft.au=Rosello%2C+Rosa&rft.date=2023-03-01&rft.eissn=2056-5933&rft.volume=9&rft.issue=1&rft_id=info:doi/10.1136%2Frmdopen-2022-002936&rft_id=info%3Apmid%2F36927849&rft.externalDocID=36927849 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-5933&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-5933&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-5933&client=summon |